Suggested remit: To appraise the clinical and cost effectiveness of Iclepertin (BI 425809) within its marketing authorisation for treating schizophrenia
Suggested remit: To appraise the clinical and cost effectiveness of Iclepertin (BI 425809) within its marketing authorisation for treating schizophrenia